With Sagent Pharmaceuticals operating in an increasingly competitive US injectables market, the company has recently been making moves to bolster its position in the wake of its separation last year from its former parent company, Japan’s Nichi Iko. Chief executive Vishy Chebrol talks to Generics Bulletin about the firm’s strategic goals.

Seven years after it paid almost three quarters of a billion dollars for US-based Sagent, troubled Nichi-Iko is offloading the struggling business.

Troubled Japanese firm Nichi-Iko has currently has ¥55.8bn of debt forgiveness, which may expand to ¥98.5bn in the future. It currently faces regular payments until 2033 to settle all of its debts.

Nichi-Iko still has a long road to recovery ahead as it attempts to get its Toyama plant back on its feet.